• Profile

Ivermectin drug not to be included in Centre's COVID management protocol

PTI Oct 23, 2020

Ivermectin, an antiparasitic drug, being touted as a possible treatment for the coronavirus infection will not be included in the Health Ministry's Clinical Management Protocol for COVID-19, sources said on October 22.

For our comprehensive coverage and latest updates on COVID-19 click here.

Some states including Uttar Pradesh are already using the drug-off label not only as a treatment option but also as a prophylaxis against COVID-19, a source said. Already widely used against intestinational parasites and scabies, it is relatively a safe and cheap drug. The experts of the ICMR's National Task Force for COVID-19 and the Joint Monitoring Group held its meeting on October 22 to deliberate on whether the drug should be included in the national treatment guidelines. "Following deliberations, experts decided not to include Ivermectin in the national clinical management protocol for COVID-19 because of lack of sufficient evidence on its efficacy based on randomised trials held in India and abroad," a source said.

The Health Ministry has allowed the use of remdesivir for restricted emergency use purposes in moderate cases under investigational therapies" in the Clinical Management Protocol for COVID-19. The ministry has also okayed off-label application of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma for treating COVID-19 patients in moderate stage of the illness as investigational therapies".

It also recommended hydroxychloroquine in patients during the early course of the disease and not on critically ill patients. The centre has also included an inexpensive, widely used steroid dexamethasone in treatment protocols for COVID-19 patients in the moderate to severe stages of their illness among other therapeutic measures. The ministry advised use of dexamethasone, which is already used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects, as an alternative choice to methylprednisolone for managing moderate to severe cases of coronavirus infection.

Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen